Slingshot members are tracking this event:

TapImmune Doses First Patient in Its Phase 2 Triple Negative Breast Cancer Trial for Cancer Vaccine TPIV 200

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details
The randomized, open label Phase 2 study is expected to enroll a total of 80 subjects. The primary endpoints are dosing regimens and safety. Secondary endpoints are T-cell specific responses and evaluation of objective responses.

"Enrollment has started in the Phase 2 40 patient study at Memorial Sloan Kettering in collaboration with Astra Zeneca in late-stage ovarian cancer. In addition, the large 280 patient Phase 2 trial being run at the Mayo Clinic with a grant from the Department of Defense is expected to start enrollment later this year," Dr. Wilson added.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 21, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Tpiv 200